Adam Bubes

George Notter

Scott Searle

- CAMP4 Therapeutics Corporation has **initiated GLP toxicology studies** for its lead product candidate, **CMP-SYNGAP-01**, as of October 1, 2025.  **[1736730_0001736730-25-000074_a20251001exhibit991.htm:0]** 
- These studies are a critical step towards a planned clinical trial application, which could enable the initiation of a **first-in-human Phase 1/2 clinical trial** for SYNGAP1-related disorders as early as the **second half of 2026**.  **[1736730_0001736730-25-000074_a20251001exhibit991.htm:0]** 
- CMP-SYNGAP-01 is an investigational therapeutic designed to upregulate SYNGAP1 gene expression to restore SYNGAP protein levels, addressing SYNGAP1-related disorders for which there are **no FDA-approved disease-modifying therapies**.  **[1736730_0001736730-25-000074_a20251001exhibit991.htm:0]** 
- Preclinical studies have demonstrated **robust activity** for CMP-SYNGAP-01, including restoring SYNGAP1 protein levels in a mouse model and increasing SYNGAP1 protein in non-human primate brain regions.  **[1736730_0001736730-25-000074_a20251001exhibit991.htm:0]**

Camp4 Therapeutics (CAMP)